Spero Therapeutics Inc

SPRO

NASDAQ. Currency in USD

1.75 -0.07 ( -3.85% )

Real time prices: December 09

Market Cap.
90.61M
Beta (5Y monthly)
0.76
Price/Earnings
-
EPS (TTM)
-3.11
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
664,404
1y Target Est.
6.33
Day's Range
1.72
-
1.78
52 Week's Range
0.68
-
16.30

Historical Summary

Performance
EPS growth
Share Buybacks

About Spero Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://sperotherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
32.32M
Employees
41
Address
675 Massachusetts Avenue, Cambridge, MA, United States, 02139
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Latest news

Spero Therapeutics to Present Data at IDWeek 2022
Spero Therapeutics to Present Data at IDWeek 2022

CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset...
By GlobeNewswire Inc. - 7 weeks ago

Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

Event is taking place on Thursday, October 6th at 11:30 a.m. ET
By GlobeNewswire Inc. - 9 weeks ago

Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October
Cheap Stocks To Buy Now? Hot Penny Stocks To Watch In October

Hot penny stocks to watch for October. The post Cheap Stocks To Buy Now? Hot...
By PennyStocks - 10 weeks ago

Hot Penny Stocks To Watch As The Stock Market Crash Continues
Hot Penny Stocks To Watch As The Stock Market Crash Continues

Hot penny stocks to add to your watch list this week. Is it time to...
By PennyStocks - 10 weeks ago

Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its...
By Zacks Investment Research - 11 weeks ago

Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce
Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce

Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2...
By Benzinga - 11 weeks ago